BioMarin Pharmaceutical
BMRN
$64.45
-2.95%
BioMarin Pharmaceutical Inc. is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases, with a portfolio spanning enzyme replacement therapies, gene therapies, and other advanced treatments across eight approved products targeting conditions such as achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. As a specialist in orphan drug development, BioMarin occupies a distinct niche in the biotechnology landscape, combining the commercial infrastructure of a mid-cap biopharma with the pipeline optionality of a research-driven innovator, and its VOXZOGO franchise for achondroplasia has become the central pillar of its growth narrative. The current investor debate centers on two competing forces: the successful Phase 3 trial of VOXZOGO in hypochondroplasia, which validates pipeline expansion into a significant new market, and the emerging competitive threat from BridgeBio's rival achondroplasia candidate, which recently posted strong trial data and plans an FDA filing in 2026. BioMarin's strategic response, converting a competitive threat into a royalty-bearing asset through a deal with Ascendis, has added a layer of financial optionality, though investors remain watchful for potential market share erosion and future oral competitors that could pressure the franchise over the medium term.…
BMRN
BioMarin Pharmaceutical
$64.45
Related headlines
Investment Opinion: Should I buy BMRN Today?
Based on the synthesis of valuation, growth, and risk factors, BioMarin earns a Hold rating with a positive bias. The core thesis is that the stock is undervalued on a price-to-sales basis (3.54x vs. peers at 5x-8x) and offers 39.2% upside to the average analyst target of $91.42, but near-term competitive and earnings risks warrant caution until there is more clarity on the VOXZOGO franchise's durability. The consensus 'buy' rating (mean 1.74) and stable institutional support provide a constructive backdrop, but the recent 6.5% monthly decline and negative relative strength suggest the market is in a wait-and-see mode.
Supporting evidence for the Hold rating includes: 1) Revenue growth of 17.0% year-over-year in Q4 2025, driven by a diversified rare disease portfolio; 2) A trailing gross margin of 77.1%, though Q4's 66.3% shows volatility; 3) Strong free cash flow of $725.0 million (6.4% FCF yield) and a cash-rich balance sheet with $1.31 billion in cash and a current ratio of 5.21; and 4) A forward PE of 10.04x, which is attractive if the aggressive EPS estimate of $9.59 is achieved, but the trailing PE of 32.65x and negative PEG ratio of -1.71 highlight earnings uncertainty. The PS ratio of 3.54x is well below the sector's typical 5x-8x range, suggesting the market is pricing in competitive headwinds.
The biggest risks that could invalidate the Hold thesis are: 1) BridgeBio's achondroplasia candidate gaining FDA approval in 2026 and capturing significant market share, which would pressure VOXZOGO revenue; 2) A continued decline in gross margin below 70%, signaling pricing pressure; and 3) Downward revisions to the forward EPS estimate, which currently implies a more than 300x increase from trailing EPS. The rating would upgrade to Buy if the stock pulls back to the $60 support level (analyst low target) while revenue growth remains above 15%, or if BridgeBio's competitive threat diminishes. It would downgrade to Sell if VOXZOGO revenue declines sequentially for two consecutive quarters or if gross margin falls below 65%. Relative to its own history (PS high of 35.8x in Q4 2022) and peers, the stock appears undervalued, but the discount is justified by competitive risks.
Sign up to view all
BMRN 12-Month Price Forecast
BioMarin presents a balanced risk/reward profile with a neutral stance. The stock is attractively valued on a price-to-sales basis (3.54x) relative to peers, and the strong balance sheet ($1.31 billion cash, 5.21 current ratio) provides a margin of safety. However, the competitive threat from BridgeBio and the recent earnings volatility (Q4 net loss, margin compression) create near-term uncertainty. The analyst consensus is bullish, but the wide target range reflects divergent views on the VOXZOGO franchise's durability. I would upgrade to bullish if the stock pulls back to the $60 support level while revenue growth remains above 15%, or if BridgeBio's competitive threat diminishes. I would downgrade to bearish if VOXZOGO revenue declines sequentially for two consecutive quarters or if gross margin falls below 65%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on BioMarin Pharmaceutical's 12-month outlook, with a consensus price target around $91.42 and implied upside of +41.9% versus the current price.
Average Target
$91.42
0 analysts
Implied Upside
+41.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$60 - $124
Analyst target range
BioMarin is covered by 26 analysts, with a consensus recommendation of "buy" and a recommendation mean of 1.74 (where 1.0 is a strong buy and 5.0 is a strong sell), indicating a moderately bullish consensus. The average target price is $91.42, which implies approximately 39.2% upside from the current price of $65.68, a substantial expected return that suggests analysts see significant value in the stock. The consensus leans bullish, supported by the recent institutional ratings showing predominantly Buy or Overweight actions from firms including B of A Securities, Barclays, and Wells Fargo, with no downgrades to Sell or Underperform in the visible data. The estimated revenue average of $5.53 billion and EPS average of $9.59 for the forward period underpin this optimism, though the EPS estimate appears aggressive relative to the trailing $0.03.
The target price range spans from a low of $60.00 to a high of $124.00, a wide spread of 107% that signals high uncertainty and divergent views on the company's prospects. The high target of $124 likely assumes successful VOXZOGO expansion into hypochondroplasia, sustained 17%+ revenue growth, and significant margin expansion that drives the forward EPS estimate, while the low target of $60 (just 8.6% below the current price) prices in competitive erosion from BridgeBio and other rivals, potential pricing pressure, and limited pipeline success. The wide spread is characteristic of a binary biotech catalyst story, where the outcome of competitive dynamics and pipeline readouts will determine whether the stock re-rates toward the high end or stagnates near the low end. The recent institutional ratings show a stable pattern of reiterations rather than upgrades or downgrades, suggesting analysts are in a wait-and-see mode ahead of key competitive and pipeline milestones, and the lack of recent downgrades despite the 1-month price decline indicates that the sell-side remains constructive on the long-term thesis.
Drowning in data?
Find the real signal!
Bulls vs Bears: BMRN Investment Factors
The bull case for BioMarin rests on a deep valuation discount (PS of 3.54x vs. peers at 5x-8x), a strong balance sheet with $1.31 billion in cash, and pipeline catalysts like the VOXZOGO hypochondroplasia opportunity that could drive significant upside toward the $91.42 average analyst target. However, the bear case is gaining traction due to earnings volatility (Q4 2025 net loss of $46.6 million), competitive threats from BridgeBio's achondroplasia candidate, and a sharp Q4 gross margin decline to 66.3%. Currently, the bear evidence appears slightly stronger given the recent 6.5% monthly decline and negative relative strength, but the valuation cushion and analyst consensus provide a counterbalance. The single most important tension is whether VOXZOGO can maintain its franchise dominance in the face of BridgeBio's impending FDA filing in 2026—if BioMarin successfully defends its market share, the stock could re-rate toward the high end of analyst targets; if not, the low target of $60 could be tested.
Bullish
- Deep valuation discount to peers: BMRN trades at a PS ratio of just 3.54x and a PB of 1.87x, well below the typical 5x-8x PS and 3x-5x PB range for profitable mid-cap biotechs. This discount persists despite a 77.1% gross margin and 17.0% revenue growth, suggesting the market is overly pessimistic about competitive threats.
- Analyst consensus sees 39% upside: With 26 analysts covering the stock, the consensus rating is 'buy' (mean 1.74) and the average target price of $91.42 implies 39.2% upside from the current $65.68. The high target of $124 suggests significant optionality if pipeline catalysts deliver.
- Fortress balance sheet enables pipeline funding: BioMarin holds $1.31 billion in cash with a current ratio of 5.21 and a debt-to-equity ratio of only 0.106, providing ample liquidity to fund R&D without dilutive equity raises. Trailing free cash flow of $725.0 million (6.4% FCF yield) further supports internal investment.
- VOXZOGO hypochondroplasia success opens new market: The successful Phase 3 trial of VOXZOGO in hypochondroplasia validates pipeline expansion beyond achondroplasia, potentially adding a significant new patient population. This catalyst drove a sharp stock rally in May 2026 and underpins the long-term growth narrative.
Bearish
- Earnings volatility and recent quarterly loss: Q4 2025 net income was -$46.6 million (EPS -$0.24), a stark reversal from Q2 2025's $240.5 million profit (EPS $1.25). This volatility, driven by a surge in R&D to $409.5 million in Q3, raises concerns about earnings predictability and the sustainability of the forward EPS estimate of $9.59.
- BridgeBio competitive threat intensifies: BridgeBio's rival achondroplasia candidate posted strong Phase 3 data and plans an FDA filing in 2026, directly threatening VOXZOGO's market share. The competitive overhang has likely contributed to the stock's 6.5% decline over the past month, underperforming the S&P 500 by 5.4 percentage points.
- Gross margin compression in Q4: Q4 2025 gross margin fell to 66.3% from 82.0% in Q3 and 81.8% in Q2, a significant sequential decline. While trailing gross margin remains strong at 77.1%, the sharp drop could signal pricing pressure or unfavorable product mix that may persist.
- Forward EPS estimate appears aggressive: The forward PE of 10.04x is based on an estimated EPS of $9.59, which would represent a more than 300x increase from the trailing EPS of $0.03. Such an aggressive estimate may be vulnerable to downward revisions if revenue growth decelerates or expenses remain elevated.
BMRN Technical Analysis
BioMarin is in a sustained recovery uptrend, with the stock up 17.47% over the past year and 17.39% over the trailing three months, though it remains 7.5% below its 52-week high of $70.98. At the current price of $65.68, the stock is trading at approximately 92.5% of its 52-week range (calculated as ($65.68 - $49.26) / ($70.98 - $49.26)), positioning it near the upper end of its annual band. This positioning suggests the market has largely priced in the positive pipeline catalysts, but the failure to reclaim the highs implies lingering resistance and some profit-taking pressure rather than outright distribution. The 1-year gain of 17.47% also modestly outperforms the S&P 500's 16.22% over the same period, with a relative strength of +1.25%, indicating the stock is a slight leader but not a dramatic outperformer.
Short-term momentum has decelerated sharply, with the stock down 6.49% over the past month versus a 1.06% decline in SPY, producing a negative relative strength of -5.43% that signals meaningful underperformance. This 1-month weakness diverges from the positive 3-month (+17.39%) and 6-month (+12.25%) trends, suggesting the recent pullback is a consolidation phase following a strong summer rally rather than a full trend reversal. The stock's beta of 0.238 is remarkably low, indicating it moves less than a quarter as much as the broader market, which explains the muted volatility but also means the recent 6.49% decline is significant in the context of its own historical behavior. Volume of approximately 1.6 million shares is moderate, and the short ratio of 4.37 days suggests short sellers are not aggressively positioned, reducing the risk of a violent short squeeze but also implying limited contrarian fuel for a sharp rebound.
Key technical support rests at the 52-week low of $49.26, with a secondary support zone likely forming around the $60-$62 area where the stock consolidated in late July and early August before its breakout. Resistance is defined by the 52-week high of $70.98, and a decisive breakout above this level would signal renewed momentum and likely attract trend-following capital, potentially opening a path toward the analyst high target of $124. Conversely, a breakdown below $60 would suggest the August rally was a false breakout and could expose the stock to a retest of the $50-$55 range. The maximum drawdown of -22.49% over the period underscores that despite the low beta, the stock is not immune to sharp corrections, and position sizing should account for the possibility of a 20%+ drawdown even in a relatively stable market environment.
Beta
0.24
0.24x market volatility
Max Drawdown
-22.5%
Largest decline past year
52-Week Range
$49-$71
Price range past year
Annual Return
+21.3%
Cumulative gain past year
| Period | BMRN Return | S&P 500 |
|---|---|---|
| 1m | -4.3% | -2.4% |
| 3m | +17.1% | +2.2% |
| 6m | +17.1% | +14.8% |
| 1y | +21.3% | +14.6% |
| ytd | +8.4% | +11.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BMRN Fundamental Analysis
BioMarin's revenue trajectory remains solidly growth-oriented, with Q4 2025 revenue of $874.6 million representing 17.03% year-over-year growth, building on Q3 2025 revenue of $776.1 million and Q2 2025 revenue of $825.4 million. The product segment dominates the revenue mix at $859.3 million versus just $15.2 million from royalties and other, meaning the commercial portfolio is the primary growth engine, with VOXZOGO and enzyme replacement therapies driving the expansion. The multi-quarter trend shows some lumpiness, with Q4 revenue exceeding Q3 by 12.7% but Q2 exceeding Q3, suggesting quarterly variability that is typical of rare disease franchises with concentrated patient populations. The 17% YoY growth rate is healthy for a mid-cap biotech and implies the company is successfully penetrating existing markets while benefiting from new indications, though the competitive dynamics around achondroplasia will be critical to sustaining this pace.
Profitability is inconsistent and heavily influenced by one-time items, with Q4 2025 net income of -$46.6 million and EPS of -$0.24 contrasting sharply with Q2 2025 net income of $240.5 million and EPS of $1.25. The trailing gross margin of 77.13% is strong and characteristic of a specialty biopharma with pricing power, but the Q4 gross margin of 66.26% was depressed relative to the 81.95% in Q3 and 81.82% in Q2, likely due to product mix or inventory adjustments. The operating margin of 16.56% on a trailing basis is respectable but well below the 33.55% operating margin achieved in Q2 2025, highlighting the volatility introduced by R&D spending, which surged to $409.5 million in Q3 versus $161.3 million in Q2. The net margin of 10.83% is positive but thin for the sector, and the path to consistent profitability will depend on whether the company can control operating expense growth while scaling revenue.
The balance sheet is exceptionally strong, with a current ratio of 5.21, a debt-to-equity ratio of just 0.106, and $1.31 billion in cash at the end of Q4 2025, providing substantial financial flexibility. Free cash flow on a trailing twelve-month basis is $725.0 million, and the company generated $99.6 million in operating cash flow in Q4 2025 despite the net loss, demonstrating the non-cash nature of many of its charges. ROE of 5.73% and ROA of 3.26% are modest but positive, and the interest coverage ratio of 28.6x indicates the company has no difficulty servicing its debt. The FCF yield, while not explicitly provided, can be approximated from the $725.0 million FCF against a market cap of $11.4 billion, implying a yield of roughly 6.4%, which is attractive for a growth biotech and suggests the company can fund its pipeline internally without dilutive equity raises.
Quarterly Revenue
$874565000.0B
2025-12
Revenue YoY Growth
+17.0%
YoY Comparison
Gross Margin
66.3%
Latest Quarter
Free Cash Flow
$724956000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BMRN Overvalued?
Because BioMarin's trailing net income is positive (EPS of $0.031), the PE ratio is the appropriate primary valuation metric, and the trailing PE of 32.65x compares to a forward PE of just 10.04x, a dramatic 69% compression that implies the market expects earnings to more than triple over the next year. This gap is unusually wide and reflects the analyst consensus EPS estimate of $9.59 for the forward period, which is a massive step-up from the trailing $0.03 and suggests the market is pricing in a transformational earnings inflection. However, the negative PEG ratio of -1.71 and the trailing PE's sensitivity to a near-zero earnings base make the PE less reliable than the PS ratio of 3.54x, which is more stable and better reflects the company's revenue-generating capacity.
On a peer comparison basis, BioMarin's PS ratio of 3.54x is notably below the biotechnology sector's typical range of 5x-8x for profitable mid-caps, suggesting the stock trades at a discount to its peer group despite its 77% gross margin and growing revenue base. The EV/Sales of 4.70x and EV/EBITDA of 18.73x are also moderate for a company with a 17% revenue growth rate, though the EBITDA multiple is distorted by the negative EBITDA in Q4 2025. The PB ratio of 1.87x is low relative to the sector's 3x-5x range, which could indicate the market is undervaluing the company's asset base or is concerned about the sustainability of returns on those assets. The premium/discount assessment is complicated by the earnings volatility, but on a revenue and book value basis, BioMarin appears to be trading at a discount to where comparable rare disease peers with similar growth profiles typically trade.
Historically, BioMarin's PS ratio has ranged from a high of 35.8x in Q4 2022 to a low of 12.7x in Q2 2025, and the current 3.54x is dramatically below even the lowest point in that historical range, which is a striking divergence. This compression reflects the market's reassessment of the company's growth durability amid competitive threats, but it also suggests that if the company can sustain its 17% growth rate and deliver on the forward EPS estimates, the stock could be significantly undervalued. The historical PE ratio has been extremely volatile, swinging from -19,329x in Q4 2022 to 10.9x in Q2 2025, which underscores that earnings-based metrics are unreliable for this stock and that the PS ratio is the more consistent valuation anchor. At 3.54x sales, the stock is pricing in a substantial deceleration from historical norms, and any positive surprise on the competitive or pipeline front could drive meaningful multiple expansion.
PE
32.7x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 11x~223x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
18.7x
Enterprise Value Multiple
Investment Risk Disclosure
BioMarin's financial risks are primarily tied to earnings volatility and margin pressure rather than balance sheet distress. The company reported a Q4 2025 net loss of $46.6 million (EPS -$0.24), a sharp reversal from Q2 2025's $240.5 million profit, driven largely by a spike in R&D spending to $409.5 million in Q3. Gross margin also compressed to 66.3% in Q4 from 82.0% in Q3, and while the trailing gross margin of 77.1% remains healthy, the sequential decline raises concerns about pricing power or product mix. With a debt-to-equity ratio of only 0.106 and $1.31 billion in cash, solvency is not a near-term risk, but the company's ability to consistently generate profits depends on controlling operating expenses while scaling revenue.
Market and competitive risks are significant, centered on the achondroplasia franchise. BridgeBio's rival candidate posted strong Phase 3 data and plans an FDA filing in 2026, which could erode VOXZOGO's market share and pressure pricing. The stock's low beta of 0.238 means it is less sensitive to broad market swings, but it also means company-specific news drives performance; the 6.5% one-month decline amid a 1.1% S&P 500 drop illustrates this vulnerability. Additionally, the wide analyst target range of $60 to $124 (a 107% spread) reflects high uncertainty, and any negative pipeline or competitive development could trigger a sharp re-rating. Sector rotation away from biotech or a rising interest rate environment could also compress the already discounted PS multiple of 3.54x.
The worst-case scenario involves BridgeBio gaining FDA approval and rapidly capturing market share, forcing BioMarin to lower VOXZOGO guidance and slash R&D, which would undermine the pipeline narrative. In this scenario, the stock could retest its 52-week low of $49.26, representing a 25% decline from the current price of $65.68. The analyst low target of $60 implies a more modest 8.6% downside, but the historical max drawdown of -22.49% suggests that a 20%+ correction is plausible even without a catastrophic outcome. Investors could lose 25% in a severe competitive erosion scenario, with the $49.26 level serving as a key downside reference.
FAQ
The most severe risk is competitive: BridgeBio's achondroplasia candidate posted strong Phase 3 data and plans an FDA filing in 2026, which could erode VOXZOGO's market share and pressure pricing. Financial risks include earnings volatility, highlighted by a Q4 2025 net loss of $46.6 million and a gross margin decline to 66.3% from 82.0% in Q3. Macro risks are relatively muted due to the low beta of 0.238, but sector rotation away from biotech could compress the PS multiple further. Company-specific risks include pipeline setbacks in gene therapy or enzyme replacement programs, and the aggressive forward EPS estimate of $9.59, which may be vulnerable to downward revisions. Ranked by severity: competitive threat, earnings volatility, pipeline risk, and valuation compression.
The 12-month forecast includes three scenarios: a bull case (25% probability) with a target range of $91.42 to $124.00, driven by successful VOXZOGO expansion and competitive defense; a base case (55% probability) with a target range of $70.00 to $85.00, assuming mid-teens revenue growth and stable margins; and a bear case (20% probability) with a target range of $49.26 to $60.00, triggered by BridgeBio's market entry and revenue deceleration. The base case is most likely, hinging on BioMarin maintaining its competitive position and delivering on analyst estimates. Key assumptions include revenue growth of 15-18%, gross margin stabilizing around 75-78%, and no major competitive entry before 2027.
BioMarin appears undervalued on a price-to-sales basis, trading at 3.54x compared to the biotechnology sector's typical 5x-8x range for profitable mid-caps. The PB ratio of 1.87x is also below the sector's 3x-5x range, and the EV/Sales of 4.70x is moderate for a company with 17.0% revenue growth. However, the trailing PE of 32.65x and negative PEG ratio of -1.71 reflect earnings volatility, making the PS ratio a more reliable metric. The market is pricing in significant competitive headwinds, as the current PS is dramatically below the historical high of 35.8x in Q4 2022. If BioMarin sustains its growth trajectory and delivers on the forward EPS estimate of $9.59, the stock could re-rate higher, but the discount is currently justified by uncertainty.
From a risk/reward perspective, BMRN offers a favorable setup for patient investors, with 39.2% upside to the average analyst target of $91.42 and a valuation discount (PS of 3.54x vs. peers at 5x-8x). However, the stock faces near-term headwinds from BridgeBio's competitive threat and recent earnings volatility, including a Q4 2025 net loss of $46.6 million. The biggest downside risk is a retest of the 52-week low of $49.26, representing a 25% decline, if BridgeBio gains FDA approval and erodes VOXZOGO's market share. For long-term investors comfortable with binary biotech catalysts, the current price offers an attractive entry point, but short-term traders may want to wait for a breakout above $70.98 or a pullback to $60 for a better risk/reward.
BMRN is better suited for long-term investment due to its binary pipeline catalysts, low beta of 0.238, and lack of dividend (payout ratio of 0), which means returns depend on capital appreciation over time. The company's growth stage—mid-cap biotech with a dominant rare disease franchise—and earnings visibility that is improving but still volatile make it a hold for at least 2-3 years to realize the full value of the VOXZOGO franchise and pipeline. Short-term trading is less attractive given the low beta and the 6.5% monthly decline, which could persist until competitive clarity emerges. A suggested minimum holding period is 18-24 months, allowing time for BridgeBio's competitive impact to be assessed and for BioMarin's pipeline to mature.
